Canopy Growth Corporation
Is Canopy Growth (CGC) Stock a Good Bet After the Slide?
Which Marijuana Stocks Are Popular on Reddit?
Gauging the Bullish-Bearish Sentiment on Aphria
The short interest position on a stock is one quick way to gauge the bullish and bearish sentiment on a stock.
Analysts’ Estimates for Canopy Growth’s Earnings
Canopy Growth (WEED) (CGC) is expected to report a loss per share of ~0.15 Canadian dollars.
Election Over, Market Still Undecided
We know the nation is politically divided, and now the market is showing us its split personality as well.
Do CGC, ACB, TLRY, and APHA Look Cheap?
With the exception of Aphria, Tilray, Canopy Growth, and Aurora Cannabis were trading at a premium to the peer median EV-to-EBITDA multiple.
Here’s What Jim Cramer Had to Say about the Cronos-Altria Deal
Jim Cramer said Altria’s acquisition of a 45% stake in Cronos Group last week was a “smart move” for Altria.
Cronos Group Invests in the Future
Through Cronos Group’s partnership with Ginko Bioworks, the company aims to produce cannabis through fermentation.
Aurora Cannabis: Analysts’ Projections
Analysts expect Aurora Cannabis to report a gross income of 177 million Canadian dollars in 2019 and 508 million Canadian dollars in 2020.
Does Cronos Group Look Expensive Compared to Its Peers?
Cronos Group (CRON) has been on a declining trend for a while. The stock rose to a peak of ~30 Canadian dollars in February.
Markets Rebound but Cannabis Stock Performance Is Mixed
Markets rebounded today after the recent sell-off fueled by US-China trade tensions.
Marijuana Legalization: More Americans Are Saying Yes
Marijuana legalization is gathering steam as one of the key topics for the 2020 presidential election. Marijuana is still a federally controlled substance.
Marijuana Movement: Why Do Celebrities Support It?
Marijuana is gaining more and more attention. What’s caught the most attention is that many celebrities are joining the growing support movement.
Why Aurora Cannabis Calls Itself a ‘Medical Company at Heart’
Aurora Cannabis (ACB) reported its Q2 earnings yesterday, which gave us a glimpse of recreational cannabis sales activity and what to expect from peers’ (MJ) upcoming earnings.
What Does President Trump Think about Marijuana?
President Trump hasn’t directly supported or opposed marijuana. In the past, he said that marijuana makes people “lose IQ points.”
Canaccord Genuity Raises Price Target for Canopy Growth
On February 18, Canopy Growth (WEED) received a price target upgrade from Canaccord Genuity.
Top Developments in the Cannabis Industry’s Early Years
In the second half of 2018, the cannabis industry remained busy. As the cannabis sector experienced a boom, there was a lot of excitement among investors.
Why Vaping May Not Be a Gold Mine for Cannabis Players
In recent years, vaping devices or e-cigarettes have been considered safer than tobacco cigarettes. However, the rise in vaping is now a matter of concern.
Aurora Cannabis’s Revenue: Here’s What Analysts Expect
Aurora Cannabis is set to release its fiscal 2020 first-quarter earnings results on November 11. Let’s see what analysts expect for its upcoming quarter.
Aurora Cannabis’s Price Target Cut by 30%
Aurora Cannabis (ACB) stock is currently down 29.23% on the NYSE on a YTD (year-to-date) basis. The company has lost 14.81% of its value since October 1.
Marijuana Policy: Can California Shape It for the US?
Marijuana reform has always been important in California, which became the first state to legalize medical marijuana in 1996.
Cannabis Industry Heats Up, Trump Might Ban Vaping
Cannabis legalization is heating up. More states are coming forward to legalize marijuana. Cannabis is also gaining global popularity.
Cannabis Legalization: Four Governors Met in New York
The Day reported that New York, New Jersey, Connecticut, and Pennsylvania’s governors met and agreed on basic guidelines for legalizing marijuana.
Cannabis Investment: How to Buy ACB, CGC, and Other Stocks
Cannabis is a hot sector that’s constantly evolving. Right now, how to buy cannabis stocks is a question that’s likely on many investors’ minds.
Canopy Growth Receives Target Price Upgrades
Cormark Securities raised its target price for Canopy Growth to 40 Canadian dollars from 33 Canadian dollars, which represents an increase of almost 21%.
Investing in CBD? Real Brands Is Making Big Moves
The CBD market is growing, and acquisitions are heating up. Real Brands is a top, under-the-radar investment candidate that should be on your radar.
Cannabis in Mexico: Legalization Bill Is Ready for Voting!
Cannabis legalization is approaching the deadline in Mexico. According to the Supreme Court, the deadline for marijuana legalization is Wednesday.
Mexico Will Attempt to Legalize Marijuana in 2020
Mexico is ready with a revised proposal to legalize marijuana this year. The Supreme Court gave lawmakers until April 30 to submit the new proposal.
Tilray Invests in ROSE LifeScience
On December 14, Tilray (TLRY) announced that it’s investing in ROSE LifeScience—a cannabis producer in Quebec.
Revisiting Valuation Multiples for Cannabis Companies
Recreational cannabis is close to being legalized in Canada, and producers are running at full bore to capture a piece of the market.
HEXO: Analysts’ Target Price and Ratings
CIBC downgraded HEXO to “neutral” from “outperform” and reduced the target price to 8.5 Canadian dollars from 9.5 Canadian dollars.
Canopy Growth Stock Rises, Oppenheimer Initiates Coverage
Oppenheimer analyst Rupesh Parikh initiated coverage on Canopy Growth stock. The analyst gave a “perform” rating with no target price.
Marijuana Legalization: House Passes SAFE Act in US
Yesterday, the House passed the Secure and Fair Enforcement Banking Act, which aims to reduce cash transactions for legitimate marijuana businesses.
What Do Analysts Recommend for Canopy Growth?
On December 16, Canopy Growth was trading at 26.79 Canadian dollars, implying a rise of 9.6% since its fiscal 2020 second-quarter earnings release.
Can Canopy Beat Q2 Estimates and Boost the Sector?
This week is important for the cannabis sector, as Canopy Growth and Aurora Cannabis are both set to report their earnings results on November 14.
Cronos Group Joins Altria to Bet on Cannabidiol Market
Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.
Cannabis and Vaping Concerns: Will the Dream Go Up in Smoke?
Cannabis legalization is a vital topic in the US. Meanwhile, vaping related deaths continue to rise. Will vaping concerns kill the US cannabis dream?
An Overview of Canopy Growth and Its Brands
Canopy Growth (CGC) announced the US launch of First & Free, its hemp-derived CBD product line. CGC offers softgels, oil drops, and creams.
Marijuana Vape Products Expected in Alberta Stores
AGLC will allow retail stores in Alberta to sell marijuana vape products. Consumers will likely be able to purchase cannabis vape products in the next two weeks.
Why Canopy Growth Isn’t Happy with Apple
Apple removed 181 vaping-related apps due to the vape crisis in the US. Canopy Growth is not happy with Apple’s move. Let’s see why.
South Dakota Plans for Marijuana Legalization amid COVID-19
Marijuana is illegal in South Dakota. However, the state decided to make both recreational and medical marijuana legal this year.
Marijuana Legalization Continues: Wisconsin Steps Up!
Marijuana laws are pretty strict in Wisconsin. Although cannabis is spreading its roots across US states, it’s still illegal at the federal level. President Trump and his administration want states to decide. Florida, New York, and Minnesota are all gearing up to legalize adult-use cannabis. Now, Wisconsin is pushing to legalize medical marijuana. Let’s see […]
Is Aphria a Good Cannabis Pick for 2020?
Aphria has successfully strengthened its position not only in Canada but also in international markets. The company reported impressive second-quarter results.
Will MedMen Deliver Any Good News in Its Q2 Earnings?
MedMen will report its earnings results for the second quarter of fiscal 2020 on Wednesday. Analysts expect 67.6% YoY revenue growth.
Cannabis 2.0: Aphria Gets Ready for Edibles Market
Cannabis 2.0 legalization will take place in Canada this month. Aphria plans to expand its consumer base in the vape and concentrates business.
Gundlach Compares Cannabis to Bitcoin
Jeffrey Gundlach predicted bitcoin’s (BTC) crash after the cryptocurrency’s peak in December 2017.
Big News: Cannabis Edibles in Alberta Stores
Many people expected the Cannabis 2.0 products, including cannabis edibles, to hit the markets by mid-December 2019. However, the products got delayed.
Kamala Harris: Presidential Candidate for Legalizing Marijuana
Senator Kamala Harris, who also announced her 2020 presidential bid, supports legalizing marijuana at a federal level.
Elizabeth Warren Unveils Plan for Marijuana Legalization
According to Warren’s new marijuana plan, the federal legalization process would start within 100 days of her taking office.
Canopy Growth: New Cannabis 2.0 Products amid COVID-19
Canopy Growth (NYSE:CGC)(TSE:WEED) still has investors’ attention despite all that the marijuana industry has gone through.
Medical Marijuana Is Booming in OK, Struggles in OH
Medical marijuana is a hit in Ohio since it allowed it in 2016. Recreational cannabis is still not allowed. Notably, data has shown that Ohio’s medical cannabis industry is booming since it started in 2019. However, the medical cannabis industry is facing some setbacks as well. So, let’s take a look at it. Ohio and […]
Marijuana Industry: Opportunities in California amid COVID-19
Marijuana is an old but growing market in California. Notably, California became the first state to legalize medical marijuana in 1996.
Medical Cannabis in Brazil Is Coming
According to a Reuters report on December 3, Brazil is ready to approve medical cannabis products. Currently, cannabis is illegal in Brazil.
Cannabis Sector 2019 Review and 2020 Outlook
Canada legalized cannabis in October 2018, so investors expected 2019 to drive marijuana sales. However, the fate of the industry took a sharp turn.
Marijuana: Will Trump Have an Edge over Biden?
With Biden strongly opposing full-scale legalization, President Trump could turn around things. President Trump might support medical marijuana legalization.
Aurora Cannabis: Analysts’ Target Price after Its Earnings
Aurora Cannabis (ACB) reported its fourth-quarter results on September 11. The results disappointed analysts and investors.
CBD: Japan Welcomes NBEV, Stock Pops
Today, New Age Beverages Corporation (NBEV) announced that it would launch its CBD (cannabidiol) based products. Share prices jumped by 14.96% to $3.20.
Marijuana Legalization: O’Rourke Blazes His 2020 Campaign
Democratic presidential candidate Beto O’Rourke is known for voicing his opinion on federal marijuana legalization. He supports marijuana legalization.
Marijuana Legalization: South Dakota Does What Trump Said!
Marijuana legalization is ramping up. Now, South Dakota is taking President Trump’s advice. The state is kicking off a petition to legalize cannabis.
Vaping Concerns Grow, FDA and FTC Investigate Juul
Vaping has become very popular. However, investigations by the FTC and FDA sparked more concerns. Juul’s vaping devices could cause seizures.
Canopy Growth: A Cannabis 2.0 Update
On December 6, Canopy Growth (CGC) disclosed its rollout plans for Cannabis 2.0 products, such as chocolates, vape pens, vape cartridges, and beverages.
Aphria: Why Jefferies Recommends a ‘Buy’
Aphria (APHA) reported its results for the first quarter of fiscal 2020 on October 15. Since then, the stock has fallen 7%.
Canopy Gets Estimates Revised by Analysts for 2020
Canopy Growth (CGC) (WEED) missed analysts’ estimates this year. Analysts had huge expectations from CGC after Canada allowed cannabis in 2018.
Tilray: Are Analysts Optimistic about Its Stock?
After Tilray’s second-quarter earnings, Benchmark reduced its target price to $80 from $120. Cowen and Company reduced the target price to $60 from $150.
Cannabis Roundup: HEXO, WEED, ACB, and CTST
The broader US markets were relatively flat today. Weakness in the cannabis sector continued, with the ETFMG Alternative Harvest ETF down 0.4%.
Cannabis 3.0: Is It on the Horizon?
On October 17, Cannabis 2.0 legalized edibles, beverages, and concentrates in Canada. As the country waits for the benefits, is Cannabis 3.0 next?
Analysts’ Outlook for Cronos Group in January
Jefferies reduced the target price for Cronos Group stock to $5.3 from $7.5. The stock’s average target price is set at 12.0 Canadian dollars.
Cannabis in Kansas: Residents Are Taking Action
Currently, 33 states and Washington, D.C., have legalized medical cannabis, but it’s illegal in Kansas. Even having a small amount is considered a crime.
Why Aurora Cannabis Stock and Peers Are Struggling
Aurora Cannabis (ACB) had a hard time this year. ACB stock had been investors’ favorite in 2018. The stock started off 2019 on a good note
Canopy Growth: Why PI Financial Suggests a ‘Sell’
Canopy Growth dragged its stock down after its unimpressive end to fiscal 2020. The company missed the revenue estimates by a huge margin.
Marijuana: Why Is Washington Changing Its Laws?
In 2012, Washington was the second state to legalize recreational marijuana. Now, the state plans to revamp its marijuana laws.
Canopy Growth Gets an Upgrade, Constellation Books Losses
Canopy Growth (CGC) (WEED) received optimistic views from analysts on Monday. Seaport Global Securities upgraded the stock to “buy” from “neutral.”
Joe Biden Won’t Legalize Cannabis—Why?
Although Joe Biden supported medical cannabis in his previous presidential campaigns, he has always opposed full-scale legalization.
Canada’s Cannabis Act C-45 Makes Progress in the Senate
On May 28, Bill C-45, Canada’s recreational cannabis legalization bill, saw further progress in the Senate.
Marijuana in Texas: Five Things You Should Know
Marijuana laws are pretty strict in Texas, but could this change? Here are five things you need to know about the state’s relationship with marijuana.
Price Target Update for Canopy Growth in January
Canopy Growth (WEED) (CGC) has continued to deepen its roots in the United States with a recent announcement that could be a game changer.
Why Canopy Growth Is Partnering with Drake
The Canadian Press reported that Canopy Growth is partnering with rapper Drake to launch a new cannabis venture, the More Life Growth Company.
Why Constellation Brands Sold Ballast Point
Constellation Brands is selling its Ballast Point craft-beer brand and certain associated production facilities and brewpubs to Kings & Convicts Brewing Co.
What Analysts Estimate for Cannabis Companies’ Earnings Margins
Let’s now look at how capacity expansion could translate into cannabis companies’ margins.
MedMen’s Must-Know Revenue Drivers
MedMen’s (MMNFF) reported revenues are generated from direct sales through its retail stores. The company has reported no material revenues from cultivation or production wholesale operations.
Cannabis Sector: A Week in Review for Sept 20
Last week, the overall cannabis sector remained subdued. Sector ETFs, such as the Horizons Marijuana Life Sciences ETF (HMMJ), closed about 8.15% lower.
Key Takeaways on the SAFE Banking Act Hearing
On Tuesday, the US Senate held a hearing on the SAFE (Secure and Fair Enforcement) Banking Act. On March 26, the House Committee passed the act. The act will need to pass the Senate before it is sent to the US president. If passed, the act would greatly help US cannabis businesses. What is the […]
Marijuana Legalization: Minnesota Welcomes You!
Marijuana legalization is an ongoing issue in the US. Currently, the District of Columbia and 11 states have legalized cannabis. Marijuana is still illegal for recreational use in Minnesota. However, the state’s voters might favor legalization. Minnesota voters are ready for marijuana legalization Minnesota hasn’t been able to come up with a legalization decision yet. […]
Which Cannabis Stocks Have Lost More than 40% in 2019?
The cannabis industry has been on a rollercoaster ride this year. CannTrust, Tilray, and KushCo stocks have fallen more than 40% in 2019.
Cannabis Legalization: Is It Time for the US to Act?
Cannabis legalization has America’s attention. A Gallup survey has shown that two-thirds of Americans want cannabis legalized now.
Cannabis 2.0 Legalization: Canada Is Ready
Federally, cannabis legalization saw daylight in Canada in 2018. The Cannabis Act legalized recreational marijuana in October 2018. Now, the country is all set for the second wave of legalization, Cannabis 2.0, which includes cannabis edibles, cannabis-infused beverages, extracts, and various other products. Let’s dig into this more. Canada’s second wave of legalization Next month, […]
Why Canopy Growth Is a ‘Buy’ before Its Earnings
Despite the surge in May, Canopy Growth is still trading at a 54.3% discount from its 52-week high of $59.74. So, should you buy the stock?
Cannabis Beverages: Why Canadians Can’t Wait
Deloitte estimates that the newly legalized cannabis beverage market could be worth 529 million Canadian dollars annually in Canada.
Why Does Jim Cramer Prefer CGC versus CRON?
Canopy Growth (NYSE:CGC) lost 25.4% in 2019. The company reported weak sales and higher-than-expected operating losses in the last two quarters.
No Cannabis Edibles in Three Provinces for Christmas
After Canada legalized cannabis edibles in October, consumers hoped to buy these products this month. However, three provinces must wait until January.
Cannabis 2.0: Aurora Cannabis Gears Up for Edibles Market
Cannabis 2.0 legalization will take place in Canada next month. Cannabis players are gearing up to expand in the edibles market.
Will Aurora Cannabis Turn the Corner in 2020?
Despite being prepared after Canada legalized recreational cannabis in 2018, Aurora Cannabis struggled to hit its revenue numbers.
Marijuana Campaigns Continue in Nebraska and Montana
Nebraska needs to collect 130,000 valid signatures from registered voters by July 8 to qualify recreational marijuana legalization for the November 2020 ballot.
Acreage Holdings Posts Disappointing Results in Q1 2020
Acreage Holdings’ first-quarter pro forma revenue grew 65% YoY (year-over-year) to $37.6 million. The revenue beat analysts’ estimates of $34.9 million.
Why Cannabis Stocks Are on the Rise
The reason cannabis stocks are rising could be because October 17 is approaching.
Was CGC a Big Mistake for Constellation Brands?
Canopy Growth (CGC) has seen dizzying ups and gloomy downs in 2019. The stock jumped up by 79.91% from $28.92 on January 2 to $52.03 on April 29.
National Access Cannabis to Get Cannabis from CannaRoyalty
Last week, National Access Cannabis signed a binding term sheet with CannaRoyalty (CRZ) to carry the latter’s products in its stores across Canada.
Canopy Growth to Get Extract Supply from MediPharm Labs
On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs.
Why Aurora Cannabis Wants to Grow Cannabis Outdoors
Aurora Cannabis (ACB) wants to grow cannabis outdoors. In July, it received Health Canada licenses for outdoor cultivation at two Canadian sites.
Could Certain Marijuana Strains Help Fight COVID-19?
The cannabis industry is doing its own research amid COVID-19. Researchers discovered that marijuana might have properties to fight the coronavirus.